Phenotypic characterisation of multiple sclerosis

Project Details

Multiple sclerosis is a disease with a broad spectrum of clinical and subclinical presentations. Our understanding of their patterns (such as frequency and topography of clinical relapses, radiologically apparent brain damage, neurological disability and cognitive impairment) is limited. New metrics enabling more detailed, in-depth phenotypisation of the disease (such as volumetric MRI or accessible instruments for screening of cognitive function) are now becoming available for use in clinical practice.

This program broadens our understanding of multiple sclerosis phenotypes. It studies the patterns and impact of clinical relapses, disability trajectories, quantitative (volumetric) MRI changes and cognitive function, with emphasis on the prognostic value of the identified patterns. It also implements volumetric MRI in clinical practice and establishes its translational value at the individual patient level.

Researchers

  • A/Prof Tomas Kalincik, Project leader
  • Dr Ai-Lan Nguyen, PhD student
  • Ms Jordana Hughes, MD student
  • Mr Jae-Kwan Jake Jun, MD student
  • Dr Johannes Lorscheider, Research associate
  • Mr Luke Perry, Research associate

Collaborators

  • The MSBase collaboration
  • Teams at Monash University
  • University of Tasmania
  • University of Newcastle
  • University of Sydney

Funding

  • NHMRC project grant 1083539, Treating progressive MS
  • NHMRC project grant 1129189, Precision treatment for multiple sclerosis
  • University of Melbourne

Research Outcomes

  1. Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, et al. on behalf of the MSBase Study Group (in press) Long-term disability trajectories in primary progressive MS in patients - a latent class growth analysis. Mult Scler, accepted 18/03/2017
  2. Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E,… Kalincik T, on behalf of the MSBase Study Group (2016) Defining secondary progressive multiple sclerosis. Brain 139(9):2395
  3. Stewart T, Spelman T, Havrdova E… Kalincik T. (2017) Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler 23(2):266-276
  4. Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, et al., on behalf of the MSBase Study Group (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138:3287-98
  5. Kalincik T (2015) Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology 44(4):199-214
  6. Uher T, Vaneckova M, Sobisek L. . . Kalincik T and Horakova D (in press) Combining clinical and MRI predictors enhances prediction of 12-year disability in multiple sclerosis. Mult Scler
  7. Uher T, Blahova Dusankova J, Horakova D, Bergsland N, Tyblova M, Benedict RHB, Kalincik T, Ramasamy DP, Seidl Z, Hagemeier J, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R (2014). Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neruol 261(9):1735-44
  8. Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Izquierdo G, Duquette P, et al., on behalf of the MSBase Study Group (2014) Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler 20:1511-22Kalincik T, Vivek V, Jokubaitis VG, Lechner Scott J, Trojano M, Izquierdo G et al., on behalf of the MSBase Study Group (2013) Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 136:3609-3617

Research Group

CORe Unit (Clinical Outcomes Research Unit)



Faculty Research Themes

Neuroscience

School Research Themes

Neuroscience & Psychiatry



Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Medicine and Radiology

Unit / Centre

CORe Unit (Clinical Outcomes Research Unit)